Yazılar

Wipro Shares Surge on Optimistic Demand Outlook

/in /tarafından

Shares of Wipro (WIPR.NS) surged approximately 8% on Monday, positioning the company for its best day in nearly four years. This sharp rise followed a positive earnings report and an optimistic outlook for future demand, echoing trends seen in its larger IT peers.

Key Highlights:

  • Strong Q3 Performance: Wipro reported better-than-expected third-quarter profits, signaling a recovery in demand within the IT services sector.
  • Optimistic Outlook: The company forecasts a 1% sequential revenue growth for the current quarter, compared to no growth last quarter. Wipro’s CEO, Srinivas Pallia, attributed this to a gradual return of discretionary spending despite ongoing macroeconomic challenges.
  • Improved Forecast: Wipro’s guidance for the upcoming quarter reflects a brighter outlook, with analysts noting that deal bookings—especially small- to mid-sized deals—point to a revival in discretionary tech spending.
  • BFSI Sector Growth: Wipro’s banking, financial services, and insurance (BFSI) segment saw an 11% increase in revenue, indicating a resurgence in spending in this key area.
  • Analyst Optimism: Following the positive earnings, at least eight brokerages raised their rating on Wipro’s stock, and 16 increased their price targets. Analysts also highlighted the company’s impressive operating margin, which reached a three-year high of 17.5%, driven by efficient deal execution.
  • Sector-Wide Optimism: Wipro’s outlook mirrors that of its larger peers, such as TCS, Infosys, and HCLTech, signaling a broader recovery within the $254 billion Indian IT services sector, which had struggled in recent quarters due to economic uncertainty and inflation.

TSMC Reports Record Quarterly Profit, Expects Strong Growth in Early 2025

/in /tarafından

Taiwan Semiconductor Manufacturing Co (TSMC) has posted a record-breaking quarterly profit, reporting a 57% increase in net income to T$374.68 billion ($11.4 billion) for the quarter ending Dec. 31. This surge in profit aligns with the company’s bullish outlook for the future, as revenue jumped by 39% compared to the same period last year. TSMC has forecasted continued strong performance, with a revenue growth estimate of about 37% for the first quarter of 2025, projecting earnings between $25-25.8 billion. For the full year, TSMC expects revenue growth to be between 20% and 30%, driven largely by the demand for chips used in artificial intelligence (AI) processing.

While TSMC’s business is thriving, it faces challenges stemming from U.S. government restrictions on AI chip exports to China. The Biden administration recently announced further curbs on these exports, which could affect demand from clients. However, TSMC’s CEO, C.C. Wei, expressed confidence that the company could manage these restrictions, stating that they are currently applying for special permits for affected clients and anticipating approval. He also emphasized the company’s strong communication with both the current and incoming U.S. administrations.

TSMC’s growth is also supported by its ambitious expansion plans, including new fabs in the United States, Japan, Germany, and Taiwan. For 2025, TSMC has set its capital spending target between $38 billion and $42 billion, marking a potential 41% increase. The AI-driven boom has significantly boosted TSMC’s stock price, which surged 81% in 2024, outperforming the broader market’s 28.5% growth.

 

Viking Therapeutics Stock Surges Nearly 30% Following Weight Loss Drug Milestone

/in /tarafından

Viking Therapeutics saw its stock jump by 28% on Thursday after the company announced it would be advancing its experimental weight loss injection, VK2735, into a late-stage trial earlier than anticipated. This move positions Viking closer to entering the lucrative GLP-1 market, which analysts project could grow to $150 billion by the end of the decade.

Viking’s accelerated timeline was influenced by feedback from the Food and Drug Administration (FDA), allowing the San Diego-based biotech firm to bypass an additional mid-stage trial. The company plans to meet with the FDA in the fourth quarter to finalize the design and timing of the phase three trial, potentially shaving a year off the drug’s development timeline. Analysts now estimate the drug could launch as early as 2029.

VK2735, a weekly injection that targets GLP-1 and GIP hormones, demonstrated promising results in a phase two trial, with patients experiencing up to 14.7% body weight loss after 13 weeks. Viking also plans to test a monthly version of the injection, which could offer a more convenient alternative to Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy, both of which are administered weekly.

In response to Viking’s announcement, shares of major competitors Eli Lilly and Novo Nordisk closed lower, down 4% and 3% respectively, reflecting market concerns over potential new competition in the weight loss and diabetes treatment space.

Viking Therapeutics is also exploring an oral version of VK2735, which showed a 3.3% weight loss compared to a placebo in an early-stage trial. As Viking pushes forward, its entry into the GLP-1 market could intensify competition among drugmakers vying for a share of this rapidly expanding sector.